Edwards Lifesciences Corporation (EW), a significant player in the Healthcare sector, has seen various fluctuations in the stock market. The firm consistently outperforms its competitors, even on strong trading days, reflecting its robust investment potential. The stock has a consensus rating of “Moderate Buy” from analysts indicating a positive outlook. Significant fund movements have taken place with notable entities like Gulf International Bank, Meyer Handelman Co., and Rise Advisors LLC strengthening their positions in Edwards Lifesciences' stock. The launch of the
SAPIEN 3 Ultra RESILIA Valve underscores the company’s innovation and commitment to improving healthcare solutions. Edwards Lifesciences plans to
spin-off its critical care unit in 2024, a strategic move anticipated to influence the company’s direction. Despite some underperformance, the stock has given a respectable return of 50% in the last five years. Negative aspects include the company's CFO selling over $492k in company stocks and an EU antitrust complaint by Meril. However, the firm recently reported positive Q4 and full-year 2023 results, potentially balancing out negative impacts.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Sun, 23 Jun 2024 12:51:28 GMT -
Rating 7
- Innovation 5
- Information 6
- Rumor 4
